Products You May Like
SEATTLE, Might 26, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical firm using refined computational strategies to design de novo protein therapeutics, immediately introduced that Jonathan Drachman, M.D., Chief Govt Officer, will current on the Jefferies Digital Healthcare Convention on Wednesday, June 2, 2021 at 10:30 a.m. Japanese Time.
A reside audio webcast of the company presentation and query and reply session to observe might be accessible from the traders part of the Neoleukin web site at https://investor.neoleukin.com/events. An archived replay may even be accessible on the corporate web site for no less than 30 days following the occasion.
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical firm creating subsequent technology immunotherapies for most cancers, irritation and autoimmunity utilizing de novo protein design know-how. Neoleukin makes use of refined computational strategies to design proteins that display particular pharmaceutical properties that present doubtlessly superior therapeutic profit over native proteins. Neoleukin’s lead product candidate, NL-201, is a mixed IL-2 and IL-15 agonist designed to enhance tolerability and exercise by eliminating the alpha receptor binding interface. For extra info, please go to the Neoleukin web site: www.neoleukin.com.
Secure Harbor / Ahead-Wanting Statements
This press launch accommodates “forward-looking” statements throughout the which means of the protected harbor provisions of the U.S. Personal Securities Litigation Reform Act of 1995, together with, however not restricted to, statements concerning the therapeutic properties and potential of the corporate’s de novo protein design know-how, the outcomes of the scientific trial for NL-201, and deliberate scientific and growth actions and timelines. Ahead-looking statements may be recognized by phrases akin to: “anticipate,” “intend,” “plan,” “aim,” “search,” “consider,” “venture,” “estimate,” “count on,” “technique,” “future,” “seemingly,” “might,” “ought to,” “will” and related references to future intervals. These statements are topic to quite a few dangers and uncertainties, together with dangers and uncertainties associated to the corporate’s money forecasts, the corporate’s means to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and outcomes of preclinical and scientific trials, the timing of bulletins and updates regarding the corporate’s scientific trials and associated information market circumstances and additional impacts of COVID-19, that might trigger precise outcomes to vary materially from what Neoleukin expects. Additional info on potential threat components that might have an effect on Neoleukin’s enterprise and its monetary outcomes are detailed below the heading “Danger Components” in paperwork the corporate information infrequently with the Securities and Change Fee (SEC), and different stories as filed with the SEC. Neoleukin undertakes no obligation to publicly replace any forward-looking assertion, whether or not written or oral, which may be made infrequently, whether or not because of new info, future developments or in any other case.
Contacts:
Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com
Buyers
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com
